Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
873 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01628536 | A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ | completed | N/A | 33 | Yale UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT03121352 | Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer | completed | Phase 2 | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT02870699 |
| Efficacy of Evonail® Solution in the Prevention of Nail Damage Induced by Docetaxel in Patients With Breast Cancer.(EVONAIL) |
| completed |
| N/A |
| 50 |
| Institut de Cancérologie de LorraineOTHER |
| 1 |
| Sep 28, 2023 |
| clinicaltrials |
| NCT00614172 | Proton Therapy for Early Stage Breast Cancer | completed | N/A | 50 | Loma Linda UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03953833 | B003 in Patients With HER2-positive Recurrent or Metastatic Breast Cancer(B003-101) | completed | Phase 1 | 30 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Sep 14, 2023 | clinicaltrials |
| NCT04032080 | LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer | completed | Phase 2 | 10 | Baylor Research InstituteOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT04081389 | Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05367739 | Real World Study on the Efficacy and Safety of Anti-HER2 Therapy | completed | — | 200 | Hunan Cancer HospitalOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT03679559 | Exercise in Improving Health and Quality of Life in Breast Cancer Survivors | completed | N/A | 83 | Roswell Park Cancer InstituteOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT02066532 | Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer | completed | Phase 1 / Phase 2 | 32 | Dawn L. HershmanOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT06007118 | Adjuvant Partial-breast Irradiation Using Stereotactic Body Radiation Therapy | completed | N/A | 85 | Masaryk Memorial Cancer InstituteOTHER | 1 | Aug 23, 2023 | clinicaltrials |
| NCT05769751 | A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer | completed | — | 865 | Daiichi SankyoINDUSTRY | 1 | Aug 16, 2023 | clinicaltrials |
| NCT02614794 | A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer(HER2CLIMB) | completed | Phase 2 | 612 | Seagen Inc.INDUSTRY | 15 | Aug 14, 2023 | clinicaltrials |
| NCT02637024 | Trial of Radiation Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation(OPAR) | completed | Phase 2 | 280 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05549687 | E-Health Support Program (PACK Health Program) in Supporting Patient Reported Symptoms in Newly Diagnosed Patients With Breast Cancer | completed | N/A | 419 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05071677 | Treatment Decision Making in African American Women Diagnosed With Triple Negative Breast Cancer | completed | — | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT03193853 | TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 12 | Joyce O'ShaughnessyOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT04022772 | Effect of PACK Health Support Program on Patient Reported Outcomes in Patients With Breast Cancer | completed | N/A | 287 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT03018080 | Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer(PePPy) | completed | Phase 2 | 40 | Wake Forest University Health SciencesOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05730010 | Discerning the Impact of ctDNA Detection on Patient Decision Making in Early Stage Breast Cancer: a Conjoint Analysis | completed | — | 289 | Indiana UniversityOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03454529 | The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer | completed | Phase 2 | 24 | Michael SimonOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05961280 | Selective Omission of Sentinel Lymph Node Biopsy in Mastectomy for Ductal Carcinoma in Situ: Identifying Eligible Candidates | completed | — | 385 | Gangnam Severance HospitalOTHER | 0 | Jul 27, 2023 | clinicaltrials |
| NCT04456140 | Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study | completed | Phase 1 | 230 | Mayo ClinicOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT03941743 | Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer | completed | Phase 1 | 2 | Mayo ClinicOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT02121873 | The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage | completed | — | 6 | Atossa Therapeutics, Inc.INDUSTRY | 1 | Jul 20, 2023 | clinicaltrials |
| NCT03599453 | Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer | completed | Early Phase 1 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT04465253 | Remotivation Process for Improving Adherence to Lymphedema Treatment Programs in Patients With Breast Cancer-Related Lymphedema | completed | N/A | 19 | City of Hope Medical CenterOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT03829436 | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers | completed | Phase 1 | 38 | Tempest TherapeuticsINDUSTRY | 1 | Jul 3, 2023 | clinicaltrials |
| NCT00309478 | Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients | completed | Phase 3 | 1,099 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 0 | Jun 29, 2023 | clinicaltrials |
| NCT01837602 | cMet CAR RNA T Cells Targeting Breast Cancer | completed | Phase 1 | 6 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT02673398 | Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer | completed | Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04902144 | Clinical Outcomes for Offering Genetic Testing in a Tiered Approach | completed | N/A | 6 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT03872791 | A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer | completed | Phase 1 / Phase 2 | 52 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Jun 8, 2023 | clinicaltrials |
| NCT00179348 | Yoga-Based Rehabilitation Program in Reducing Physical and Emotional Side Effects in Patients With Cancer | completed | N/A | 399 | Albert Einstein College of MedicineOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT02768701 | Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT00921115 | Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. | completed | Phase 2 | 42 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT02526498 | Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery(TRIUMPH-T) | completed | Phase 2 | 200 | Rutgers, The State University of New JerseyOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT02531425 | Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC(TNBC) | completed | Phase 1 | 10 | OncoSec Medical IncorporatedINDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | completed | Phase 1 | 37 | Fate TherapeuticsINDUSTRY | 1 | May 1, 2023 | clinicaltrials |
| NCT02898207 | Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer | completed | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 26, 2023 | clinicaltrials |
| NCT04857697 | Effects of Probiotics on the Gut Microbiome and Immune System in Operable Stage I-III Breast or Lung Cancer | completed | Early Phase 1 | 6 | Mayo ClinicOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT01417286 | Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer | completed | Phase 2 | 69 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 20, 2023 | clinicaltrials |
| NCT03112590 | Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer | completed | Phase 1 / Phase 2 | 51 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT01922921 | Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy | completed | Phase 1 / Phase 2 | 31 | University of WashingtonOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT03709186 | Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI | completed | — | 100 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 11, 2023 | clinicaltrials |
| NCT04297384 | Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice | completed | N/A | 174 | Roswell Park Cancer InstituteOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT03849469 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors(DUET-4) | completed | Phase 1 | 78 | Xencor, Inc.INDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03775850 | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | completed | Phase 1 | 69 | Evelo Biosciences, Inc.INDUSTRY | 2 | Mar 24, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 13, 2023source: clinicaltrials